Meeting
2020 ASCO Virtual Scientific Program
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
Authors
Alessandro Santin
Yale University School of Medicine, New Haven, CT
Alessandro Santin , Takefumi Komiya , David M. Goldenberg , Robert M. Sharkey , Quan Hong , William A. Wegener , Trishna Goswami , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01631552
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6081)
DOI
10.1200/JCO.2020.38.15_suppl.6081
Abstract #
6081
Poster Bd #
252
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin
Poster
2020 ASCO Virtual Scientific Program
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.
First Author: Ashish Saxena
Poster
2023 ASCO Annual Meeting
OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.
First Author: Russell J. Schilder
First Author: B.J. Rimel